IFNA1 and Cirrhosis: Some investigators proposed that the SVR rate in patients infected with HCV-1a or -3a, could be strongly affected by the presence of RASs in companion with a history of previous IFN-based treatment, and this negative effect was irrespective of the cirrhosis status (Walker et al., 2015; Sarrazin, 2016; Sarrazin et al., 2016; Welzel et al., 2017; Zeuzem et al., 2017; Dietz et al., 2018; Esposito et al., 2019; Smith et al., 2019).